Declaration of interests
VR received consulting fees and honoraria from EMD Serono. JM-B received grants (paid to his institution) from Abbisko Therapeutics, Biosplice, Boehringer Ingelheim, Bristol-Myers Squibb, Cebiotex, Deciphera, Eli Lilly, Immunome, Inhibrx, Karyopharm, Lixte, Pfizer, PharmaMar, Philogen, PTC Therapeutics, Rain Therapeutics, Springworks Therapy, and Synox; consulting fees from Deciphera and PharmaMar; honoraria from Abbisko Therapeutics, Adium, Bayer, Boehringer Ingelheim, Cogent Bioscience, Deciphera, GSK, PharmaMar, and Roche; travel support from PharmaMar; and is the CEO of Sarcoma Research Solutions. AAR received institutional support from 23andMe, Abbisko Therapeutics, AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cogent Biosciences, Daiichi Sankyo, Deciphera, Frontier Biopharma, Gilead, GSK, Intensity Therapeutics, Iterion Therapeutics, Karyopharm, Kelun-Biotech, MedImmune, Medison, Merck, Neoleukin Therapeutics, Novartis, Pfizer, Polaris, Roche/Genentech, Rain Therapeutics, and Symphogen; honoraria from Boehringer Ingelheim and Medison; and participated on a data safety monitoring or advisory board for CD40Life and Inhibrx. CS received honoraria from Deciphera, PharmaMar, and Roche; travel support from Bayer, Gilead, and PharmaMar; was a steering committee member for NewBay; and participated in advisory boards for Deciphera and IDRX. SS received grants (paid to her institution) from Abbisko Therapeutics, Daiichi Sankyo, Deciphera, and SynOx Therapeutics; and participated in advisory boards for Daiichi Sankyo, Deciphera, and Merck Serono. GGB received consulting fees from Eli Lilly and PharmaMar; honoraria from Eli Lilly, GSK, Istituto Gentili, MSD, and PharmaMar; travel support from Eli Lilly, Istituto Gentili, and PharmMar; and participated in advisory boards for Deciphera, GSK, and MSD. PR received research funding (paid to his institution) from Bristol-Myers Squibb, Novartis, Pfizer, Roche; consulting fees from Bristol-Myers Squibb, Genesis, Medison Pharma, MSD, Novartis, Pierre Fabre, and Philogen; honoraria from Bristol-Myers Squibb, Genesis, Medison Pharma, MSD, Novartis, and Pierre Fabre; participated in speakers bureaus for Bristol-Myers Squibb, Genesis, MSD, Novartis, and Pierre Fabre; and travel support from Pierre Fabre. GT participated in advisory boards for Deciphera and SynOx. All other authors declare no competing interests.
